Welcome to our dedicated page for ACCUSTEM SCIENCES SEC filings (Ticker: ACUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AccuStem Sciences, Inc. (ACUT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports that describe key developments in its oncology diagnostics business. AccuStem identifies itself as a clinical stage diagnostics company focused on proprietary molecular tests for patients with or at risk of cancer.
In its SEC filings, AccuStem has described the MicroRNA Signature Classifier (MSC) test as a non-invasive blood-based assay designed to assess the risk of lung cancer in individuals who qualify for low-dose computed tomography (LDCT) screening or who have indeterminate pulmonary nodules detected via imaging. The company explains that MSC analyzes 24 circulating microRNAs in plasma to classify nodules as Low or High Risk for malignancy, with the goal of helping clinicians better understand cancer risk and potentially reduce unnecessary invasive procedures for benign nodules.
Filings may also discuss AccuStem’s efforts to integrate its diagnostics into reimbursement frameworks. For example, the company has reported submitting an application for a local coverage determination with Novitas Solutions, a Medicare Administrative Contractor, to establish reimbursement for the MSC test, and noted that the application was deemed complete and valid and placed into the review queue.
On this page, users can review such SEC documents alongside AI-powered summaries that highlight the main points of each filing. These tools can help readers quickly understand disclosures related to diagnostic test descriptions, reimbursement strategies, and other material events, while still allowing access to the full original text for detailed analysis.
AccuStem Sciences Inc. (ACUT) reports a key administrative step toward Medicare reimbursement for its MSC test (MicroRNA Signature Classifier), a blood-based assay that helps assess lung cancer risk in patients eligible for low-dose CT screening or with indeterminate pulmonary nodules. The MSC test analyzes 24 circulating microRNAs in plasma to classify nodules as Low or High Risk for malignancy, which may help clinicians avoid unnecessary invasive procedures for benign nodules and focus follow-up on higher-risk patients. The company has submitted an application for a local coverage determination to Novitas Solutions, a Medicare Administrative Contractor for the JL region, and Novitas has determined that the application is complete and valid and will now enter the review queue.
AccuStem Sciences (ACUT) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of
Shares outstanding were 16,072,267 as of November 12, 2025, up from 12,100,535 at December 31, 2024, reflecting an issuance of 3,971,732 shares for
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
